Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Wobble Genomics

Explore full profile

Biochemical and bioinformatic solutions for sequencing based gene biomarker discovery

Edinburgh, United KingdomFounded 2021Biotech & Life Sciences
Valuation $50–100M Last recorded · 2024
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Wobble Genomics and the history behind them.

About Wobble Genomics

Wobble Genomics is a cutting-edge startup that focuses on enhancing the efficiency of RNA and DNA sequencing to discover and detect nucleic acid biomarkers. These biomarkers are crucial for identifying various genetic materials, including low-expressed genes and microorganisms that are present in small quantities. The company operates in the biotechnology and genomics market, serving clients such as research institutions, pharmaceutical companies, and healthcare providers who require advanced sequencing solutions for their genetic research and diagnostic needs.

The core innovation of Wobble Genomics is its "Level Up" library normalization technology. This technology optimizes the sampling process during sequencing, making it more efficient and cost-effective. Specifically, Level Up can reduce sequencing costs by up to 90% while increasing the sensitivity of detecting nucleic acid biomarkers. Unlike traditional methods that use targeted probes or depletion, Level Up ensures a uniform distribution of all unique sequences in a cDNA library. This approach allows for maximum non-targeted sequencing efficiency, which is essential for comprehensive biomarker discovery.

Wobble Genomics generates revenue by offering its Level Up technology as a service to its clients. They may charge fees based on the volume of samples processed or through licensing agreements with other companies that wish to integrate Level Up into their own sequencing workflows. By providing a solution that significantly reduces costs and improves detection capabilities, Wobble Genomics adds substantial value to its clients' research and diagnostic processes.

In summary, Wobble Genomics is revolutionizing the field of genetic sequencing with its innovative Level Up technology, making it more accessible and effective for a wide range of applications.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2021
Headquarters
Edinburgh, United Kingdom
Employees
19
Open positions
None listed
Dealroom signal
65.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, AI Drug Discovery, Techbio, Hard Tech, Techbio Drug Discovery, Digital Pharma, DT and LS
Business model
Manufacturing
Client focus
b2b

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Mar 2024 $11M $45M Mercia Asset Management · Eos Advisory · Business Growth Fund · IQ Capital ↗
SEED✓Equity / VC Sep 2021 $1.6M $6.3M Old College Capital · Eos Advisory —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Wobble Genomics website traffic

Latest recorded traffic for Wobble Genomics is 1.1K monthly website visits, down 31.3% over the last three months. Wobble Genomics's team declined 9.5% over the past year.

Latest monthly visits1.1K 3-month web change-31.3% 1-year team growth-9.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
ChemifyDigitizing chemistry by developing technology to convert chemical code into molecules and vice versa Glasgow, United Kingdom Operational 196 $104M $200M
Nucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine Oxford, United Kingdom Operational
Rosa BiotechAI-driven biosensing and diagnostics company providing outcome-focused biosensing for early disease diagnosis and for use in industrial biotechnology Bristol, United Kingdom Operational
Achilles TherapeuticsAchilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells Stevenage, United Kingdom Closed
CellVoyantAn AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases Bristol, United Kingdom Operational
Ground Truth LabsGround Truth Labs AI platform measures intricate spatial biomarkers in routine histopathology slides, aiding drug development, de-risking trials, and enhancing clinical diagnosis London, United Kingdom Operational
Lightcast DiscoveryLightcast is developing a new platform for manipulating cells and reagents, enabling game-changing workflows for pharma Cambridge, United Kingdom Operational
MacomicsDeveloping precision medicines to modulate macrophages for the treatment of cancer Edinburgh, United Kingdom Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed6 investors entered at this stage

  • Eos Advisory
  • Old College Capital
  • Mercia Asset Management
  • Business Growth Fund
  • IQ Capital
  • Edinburgh Innovations

Other known investors3 additional known investors

  • University of Edinburgh
  • Innovate UK Business Connect
  • Mercia Ventures
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇬🇧 United Kingdom82.3%
🇺🇸 United States17.6%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Wobble Genomics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Wobble Genomics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.